Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Mellinghoff
    Mellinghoff
  4. Shuman
    Shuman
  5. Rosenblum
    Rosenblum
  6. Dunkel
    Dunkel
  7. Karajannis
    Karajannis
  8. Saltz
    Saltz
  9. Souweidane
    Souweidane
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)
  7. Department of Pathology and Laboratory Medicine (415)
  8. Gastrointestinal Oncology Service (386)
  9. Genitourinary Oncology Service (367)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2108)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (92)
  5. Editorial (84)
  6. Guidelines (36)
  7. Correspondence (26)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (10)
Groups
  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Stewart Shuman (88)
  6. Marc Rosenblum (87)

More People

Years
  1. 2025 (106)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1670)
  2. Neuro-Oncology (846)
  3. JNCI: Journal of the National Cancer Institute (485)
  4. Nucleic Acids Research (210)
  5. Clinical Infectious Diseases (138)
  6. American Journal of Clinical Pathology (106)

More Publications

Results (4653)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Racial disparities in cancer presentation and outcomes: The contribution of overdiagnosis
    Journal Article

    Marcadis, A. R.; Davies, L.; Marti, J. L.; Morris, L. G. T.
    JNCI Cancer Spectrum (2020)

    Fulltext@MSK | Save
  • Body mass index and weight loss in metastatic colorectal cancer in CALGB (Alliance)/SWOG 80405
    Journal Article

    Guercio, B. J.; Zhang, S.; Venook, A. P.; Ou, F. S.; Niedzwiecki, D.; Lenz, H. J.; Innocenti, F.; Mullen, B. C.; O'Neil, B. H.; Shaw, J. E.; more...
    JNCI Cancer Spectrum (2020)

    Fulltext@MSK | Save
  • Lower rate of seropositivity to measles among young healthcare personnel in New York City
    Journal Article

    Lucca, A.; Bayoumi, N.; Ramanathan, L. V.; Sepkowitz, K.; Kamboj, M.
    Clinical Infectious Diseases (2020)

    Fulltext@MSK | Save
  • Low immunogenicity and favorable safety seen with novel regimen of tremelimumab (T) plus durvalumab (D) in patients (pts) with unresectable hepatocellular carcinoma (uHCC)
    Meeting Abstract

    Kelley, R. K.; Negro, A.; Chen, C.; Ali, S.; Standifer, N.; Watras, M.; Evans, B.; Abou-Alfa, G. K.
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • A phase (ph) II, multi-center study of the safety and efficacy of tebentafusp (tebe) (IMCgp100) in patients (pts) with metastatic uveal melanoma (mUM)
    Meeting Abstract

    Sacco, J. J.; Carvajal, R.; Butler, M. O.; Shoushtari, A. N.; Hassel, J. C.; Ikeguchi, A.; Hernandez-Aya, L.; Nathan, P.; Hamid, O.; Piulats Rodriguez, J. M.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Survival of responders to nivolumab (NIVO) + ipilimumab (IPI) as first-line treatment for advanced NSCLC in CheckMate 227, part 1
    Meeting Abstract

    Brahmer, J. R.; Ciuleanu, T. E.; Schenker, M.; Audigier-Valette, C.; Zurawski, B.; Linardou, H.; Kim, S. W.; Otterson, G. A.; Salman, P.; De La Mora Jimenez, E.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Efficacy and updated safety results from pivotal phase II trial 201 of naxitamab (Hu3F8): A humanized GD2-targeted immunotherapy for the treatment of refractory/relapsed (R/R) high-risk (HR) neuroblastoma (NB)
    Meeting Abstract

    Mora, J.; Chan, G. C.; Morgenstern, D. A.; Nysom, K.; Bear, M.; Worsaae Dalby, L.; Lisby, S.; Kushner, B. H.
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Pivotal trial 201 data on outpatient administration of naxitamab (Hu3F8), a humanized GD2 targeted immunotherapy for the treatment of refractory/relapsed (R/R) high-risk (HR) neuroblastoma (NB)
    Meeting Abstract

    Morgenstern, D. A.; Mora, J.; Chan, G. C.; Nysom, K.; Bear, M.; Worsaae Dalby, L.; Lisby, S.; Kushner, B. H.
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Patient reported outcomes (PROs) analysis for patients with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC) receiving entrectinib in the global phase II STARTRK-2 study
    Meeting Abstract

    Barlesi, F.; Wolf, J.; Ahn, M. J.; Doebele, R. C.; Paz-Ares, L.; Rolfo, C.; Siena, S.; Seto, T.; Ohe, Y.; Ou, S. H. I.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Real-world insights into patients (pts) with advanced NSCLC and MET alterations
    Meeting Abstract

    Bittoni, M.; Yang, J. C. H.; Shih, J. Y.; Peled, N.; Smit, E.; Camidge, R.; Carbone, D.; Oksen, D.; Boutmy, E.; Johne, A.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save